PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
04 avr. 2024 01h00 HE
|
PolTREG S.A.
New biomarker may facilitate monitoring T1D patients’ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw...
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11 mars 2024 02h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it...
PolTREG appoints Dan Shelly as Chief Business Development Officer
21 févr. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
30 janv. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
16 janv. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...
Diabetes Care Devices Market Size is projected to reach USD 87.15 Billion by 2030, growing at a CAGR of 6%: Straits Research
29 juin 2022 09h40 HE
|
Straits Research
New York, United States, June 29, 2022 (GLOBE NEWSWIRE) -- Diabetes is a life-threatening, chronic disorder for which there is no treatment. Diabetes is becoming a global pandemic affecting millions...